logo-loader
Deep diveHealth
viewSareum Holdings PLC

Sareum Holdings primed for progress

Snapshot

  • Lead drug being developed by partner Sierra Oncology
  • Encouraging preliminary efficacy data on SRA737 
  • Has other preclinical treatments - one autoimmune disease, one for cancer
cancer

Quick facts: Sareum Holdings PLC

Price: 0.315 GBX

AIM:SAR
Market: AIM
Market Cap: £9.67 m
Follow

 

We believe there is a clear opportunity to generate significant value for our shareholders over the next 12 months, given recent progress with both our clinical and preclinical programmes.

Dr Tim Mitchell, chief executive

 

About Sareum

Sareum Holdings PLC's (LON:SAR) most advanced programme was developed in collaboration with the Institute of Cancer Research and the CRT Pioneer Fund. It is undergoing two Phase II clinical trials conducted by licence partner Sierra Oncology

The drug developer has two other preclinical discoveries - focused on autoimmune disease and cancer.

 

SRA737

This is a checkpoint kinase 1 inhibitor, a type of drug that controls a cancer cell's response to DNA damage

. It is currently undergoing two Phase II clinical trials in patients with advanced cancer – one as a monotherapy and another in combination with low-dose gemcitabine, which is one of the most commonly commonly-prescribed chemotherapies.

Preliminary efficacy data from a phase I/II clinical trial carried out by Vancouver-based Sierra Oncology, which licensed the drug candidate in a deal worth up to US$328.5mln plus royalties, was encouraging.  

Most eye-catching among the headlines was the impact SRA737 had in harness with gemcitabine in patients with anogenital cancer, where the response rate was 30%.

 

 

What else is in the pipeline

Sareum's SDC-1801 and SDC-1802 drug candidates, which are respectively being developed to treat autoimmune diseases and cancers are progressing through pre-clinical development and should undergo first in-human clinical trials in 2020.

Both Sareum programmes have progressed well since being chosen in September 2018 for further development.

Data items arising from some of the development work are being prepared for submission to a peer-reviewed publication and a conference presentation.

 

What the boss says: Tim Mitchell, CEO 

"We are very pleased with the progress of our proprietary dual TYK2/JAK1 programmes," Mitchell said in October. 

“We believe these offer a novel oral immunotherapy approach to addressing unmet needs in autoimmune diseases and cancer and that their mechanism is gaining increasing interest from the pharmaceutical industry.

"Mitchell also remains hopeful that partner Sierra Oncology will be able to find the funds to develop cancer treatment molecule SRA737, especially after encouraging clinical results in June and good indications from pre-clinical combinations with other therapies."

 

Inflexion points 

  • Commercial licences for the late pre-clinical or early clinical stages of SDC 1801/1802
  • Sierra Oncology raises funds for development of SRA737
  • Raised £780,000 in July

 

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Sareum Holdings says taking back control of cancer technology is “good news”

Tim Mitchell, chief executive of Sareum Holdings Plc (LON:SAR) tells Proactive the company took back the rights to Aurora +FLT3 kinase inhibitors from Hebei Medical University Biomedical Engineering Center in China. He said: “The initial project did seem to work very well, good progress...

on 1/6/18

2 min read